---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-253478"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2026-06-02T20:05:28+00:00"
generated_at: "2026-06-02T20:12:51.252942+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay

## Summary
- Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.
- Deloitte & Touche ratified as independent auditor for FY2026 with 243.8M votes for.
- Non-binding advisory vote on named executive officer compensation approved: 168.1M for vs 36.4M against.
- Advisory vote on frequency of say-on-pay: annual basis chosen with 203.8M votes for one year.
- Approximately 84.86% of outstanding shares were represented at the meeting.

## SEC filing metadata
- accession: 0001193125-26-253478
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2026-06-02T20:05:28+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/d159199d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-253478
- JSON: https://secwatch.observer/filing/0001193125-26-253478.json
- Plain text: https://secwatch.observer/filing/0001193125-26-253478.txt

## Key facts
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-01
  source text: Proposal No. 3 : Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 36,396,784 345,291 Broker Non-Votes: 38,973,186
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-06-01 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-01
  source text: Proposal No. 4 : Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 360,924 630,378 67,607 Broker Non-Votes: 38,973,186
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-01
  source text: Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 169,142,295 35,742,331 Laura Sepp-Lorenzino, Ph.D. 150,094,517 54,790,109 Broker Non-Votes: 38,973,186 Both nominees were elected.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-01
  source text: Proposal No. 2 : Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 25,551 18,176 Broker Non-Votes: 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.